View ValuationDecibel Cannabis 향후 성장Future 기준 점검 4/6Decibel Cannabis은 연간 수입과 매출이 각각 85%와 7.1% 증가할 것으로 예상되고 EPS는 연간 44%만큼 증가할 것으로 예상됩니다.핵심 정보85.0%이익 성장률44.04%EPS 성장률Pharmaceuticals 이익 성장14.2%매출 성장률7.1%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트10 Jun 2026최근 향후 성장 업데이트공시 • May 23Decibel Cannabis Company Inc. Provides Earnings Guidance for the Second Quarter of 2026 and Reaffirms Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the second quarter of 2026 and reaffirms earnings guidance for the full year 2026. For the quarter, the company expects net revenue of $33 million to $35 million, implying year over year growth of 14% to midpoint of range. For the full year guidance, the company expects net revenue of $130 million to $135 million.Price Target Changed • Apr 19Price target increased by 7.7% to CA$0.23Up from CA$0.22, the current price target is an average from 3 analysts. New target price is 73% above last closing price of CA$0.14. Stock is up 125% over the past year. The company is forecast to post earnings per share of CA$0.015 next year compared to a net loss per share of CA$0.0051 last year.공시 • Apr 18Decibel Cannabis Company Inc. Provides Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the full year 2026. For the period, the company expects Net Revenue of $130 to $135 million, implying growth of 18% to midpoint of range.Price Target Changed • Apr 07Price target decreased by 7.1% to CA$0.22Down from CA$0.23, the current price target is an average from 3 analysts. New target price is 67% above last closing price of CA$0.13. Stock is up 117% over the past year. The company is forecast to post earnings per share of CA$0 for next year compared to CA$0.032 last year.공시 • Nov 20Decibel Cannabis Company Inc. Revises Revenue Guidance for Full Year 2025Decibel Cannabis Company Inc. revised revenue guidance for full year 2025. For the period, the company expects revenue of approximately USD 115 million compared to previous guidance of USD 130 million.공시 • May 22Decibel Cannabis Company Inc. Announces Earnings Guidance for the Full Year 2025Decibel Cannabis Company Inc. announced earnings guidance for the full year 2025. For the year,the company expects Net Revenue of $130 million driven by continued international growth.모든 업데이트 보기Recent updates공시 • May 23Decibel Cannabis Company Inc. Provides Earnings Guidance for the Second Quarter of 2026 and Reaffirms Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the second quarter of 2026 and reaffirms earnings guidance for the full year 2026. For the quarter, the company expects net revenue of $33 million to $35 million, implying year over year growth of 14% to midpoint of range. For the full year guidance, the company expects net revenue of $130 million to $135 million.Reported Earnings • May 22First quarter 2026 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 1Q 2025)First quarter 2026 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 1Q 2025). Revenue: CA$29.8m (up 41% from 1Q 2025). Net loss: CA$2.18m (loss widened 14% from 1Q 2025). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.New Risk • May 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$7.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CA$7.9m free cash flow). Minor Risk Market cap is less than US$100m (CA$75.0m market cap, or US$54.3m).공시 • May 13Decibel Cannabis Company Inc. to Report Q1, 2026 Results on May 21, 2026Decibel Cannabis Company Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026Price Target Changed • Apr 19Price target increased by 7.7% to CA$0.23Up from CA$0.22, the current price target is an average from 3 analysts. New target price is 73% above last closing price of CA$0.14. Stock is up 125% over the past year. The company is forecast to post earnings per share of CA$0.015 next year compared to a net loss per share of CA$0.0051 last year.공시 • Apr 18Decibel Cannabis Company Inc. Provides Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the full year 2026. For the period, the company expects Net Revenue of $130 to $135 million, implying growth of 18% to midpoint of range.Reported Earnings • Apr 17Full year 2025 earnings released: CA$0.005 loss per share (vs CA$0.032 profit in FY 2024)Full year 2025 results: CA$0.005 loss per share (down from CA$0.032 profit in FY 2024). Revenue: CA$112.7m (up 22% from FY 2024). Net loss: CA$2.92m (down 122% from profit in FY 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공시 • Apr 08Decibel Cannabis Company Inc. to Report Q4, 2025 Results on Apr 16, 2026Decibel Cannabis Company Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 16, 2026Price Target Changed • Apr 07Price target decreased by 7.1% to CA$0.22Down from CA$0.23, the current price target is an average from 3 analysts. New target price is 67% above last closing price of CA$0.13. Stock is up 117% over the past year. The company is forecast to post earnings per share of CA$0 for next year compared to CA$0.032 last year.분석 기사 • Jan 23Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 26Impressive Earnings May Not Tell The Whole Story For Decibel Cannabis (CVE:DB)Despite announcing strong earnings, Decibel Cannabis Company Inc.'s ( CVE:DB ) stock was sluggish. Our analysis...Reported Earnings • Nov 20Third quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: CA$0.002 loss per share (further deteriorated from CA$0.001 loss in 3Q 2024). Revenue: CA$32.9m (up 37% from 3Q 2024). Net loss: CA$1.34m (loss widened 152% from 3Q 2024). Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.공시 • Nov 20Decibel Cannabis Company Inc. Revises Revenue Guidance for Full Year 2025Decibel Cannabis Company Inc. revised revenue guidance for full year 2025. For the period, the company expects revenue of approximately USD 115 million compared to previous guidance of USD 130 million.공시 • Nov 07Decibel Cannabis Company Inc. to Report Q3, 2025 Results on Nov 19, 2025Decibel Cannabis Company Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 19, 2025분석 기사 • Oct 31Potential Upside For Decibel Cannabis Company Inc. (CVE:DB) Not Without RiskThere wouldn't be many who think Decibel Cannabis Company Inc.'s ( CVE:DB ) price-to-sales (or "P/S") ratio of 0.8x is...공시 • Oct 07Decibel Cannabis Company Inc., Annual General Meeting, Dec 11, 2025Decibel Cannabis Company Inc., Annual General Meeting, Dec 11, 2025.Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: CA$0.003 (vs CA$0 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.003 (up from CA$0 in 2Q 2024). Revenue: CA$29.8m (up 35% from 2Q 2024). Net income: CA$1.65m (up CA$1.59m from 2Q 2024). Profit margin: 5.5% (up from 0.3% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.New Risk • Aug 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.3% operating cash flow to total debt). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$60.6m market cap, or US$43.9m).분석 기사 • Jul 15A Piece Of The Puzzle Missing From Decibel Cannabis Company Inc.'s (CVE:DB) 29% Share Price ClimbDecibel Cannabis Company Inc. ( CVE:DB ) shares have continued their recent momentum with a 29% gain in the last month...분석 기사 • Jul 09Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Recent Insider Transactions • Jun 08Independent Chairman of the Board recently bought CA$146k worth of stockOn the 5th of June, Shawn Dym bought around 2m shares on-market at roughly CA$0.07 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Shawn's only on-market trade for the last 12 months.Reported Earnings • May 23First quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0 in 1Q 2024)First quarter 2025 results: CA$0.003 loss per share (further deteriorated from CA$0 in 1Q 2024). Revenue: CA$21.2m (up 1.4% from 1Q 2024). Net loss: CA$1.90m (down CA$2.06m from profit in 1Q 2024). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.공시 • May 22Decibel Cannabis Company Inc. Announces Earnings Guidance for the Full Year 2025Decibel Cannabis Company Inc. announced earnings guidance for the full year 2025. For the year,the company expects Net Revenue of $130 million driven by continued international growth.분석 기사 • Apr 30Concerns Surrounding Decibel Cannabis' (CVE:DB) PerformanceFollowing the solid earnings report from Decibel Cannabis Company Inc. ( CVE:DB ), the market responded by bidding up...공시 • Apr 23Decibel Cannabis Company Inc. Reiterates Earnings Guidance for the Full Year 2025Decibel Cannabis Company Inc. reiterated earnings guidance for the full year 2025. For the period, the company expects Net Revenue of $130 million driven by continued international growth.Reported Earnings • Apr 23Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: CA$0.032 (up from CA$0.004 loss in FY 2023). Revenue: CA$92.5m (down 20% from FY 2023). Net income: CA$13.6m (up CA$15.4m from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.분석 기사 • Apr 12Market Cool On Decibel Cannabis Company Inc.'s (CVE:DB) Revenues Pushing Shares 27% LowerThe Decibel Cannabis Company Inc. ( CVE:DB ) share price has fared very poorly over the last month, falling by a...분석 기사 • Feb 26Take Care Before Diving Into The Deep End On Decibel Cannabis Company Inc. (CVE:DB)With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Pharmaceuticals industry in Canada, you could be...Price Target Changed • Jan 19Price target decreased by 16% to CA$0.27Down from CA$0.32, the current price target is an average from 3 analysts. New target price is 281% above last closing price of CA$0.07. Stock is down 46% over the past year. The company is forecast to post earnings per share of CA$0.005 next year compared to a net loss per share of CA$0.0043 last year.New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 41% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (CA$46.1m market cap, or US$32.2m).Board Change • Jan 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Nadia Vattovaz is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Dec 17Price target decreased by 16% to CA$0.27Down from CA$0.32, the current price target is an average from 3 analysts. New target price is 281% above last closing price of CA$0.07. Stock is down 46% over the past year. The company is forecast to post earnings per share of CA$0.005 next year compared to a net loss per share of CA$0.0043 last year.공시 • Dec 11Decibel Cannabis Company Inc. Announces Committee ChangesDecibel Cannabis Company Inc. announced that at the annual and special meeting of shareholders held on December 10, 2024 Subsequent to the Meeting, Shawn Dym, Nadia Vattovaz and Jakob Ripshtein have been appointed and agreed to serve on the Corporation's committees, with Ms. Vattovaz to serve as chair of the Company's Audit Committee, and Mr. Ripshtein to serve as chair of its Governance, Compensation and Nominating Committee.공시 • Nov 25Decibel Cannabis Company Inc. announced that it has received CAD 3.189099 million in fundingOn November 25, 2024, Decibel Cannabis Company Inc. closed the transaction. The company issued 19,647,776 Common Shares in the capital of the Company at an issue price of CAD 0.06 per share for the gross proceeds of up to CAD 1,178,867 in its final tranche. No finders' fees were paid in connection with either the first or second closing of the Offering. The Offering is subject to the receipt of all regulatory approvals including the final approval of the TSX Venture Exchange. Certain directors and officers of the Company subscribed for an aggregate of 19,460,061 Common shares in the first and second closings of the Offering.Reported Earnings • Nov 22Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.001 profit in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (down from CA$0.001 profit in 3Q 2023). Revenue: CA$24.1m (down 20% from 3Q 2023). Net loss: CA$531.0k (down 229% from profit in 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Nov 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Shareholders have been diluted in the past year (8.2% increase in shares outstanding). Market cap is less than US$100m (CA$31.0m market cap, or US$22.3m).공시 • Oct 29+ 3 more updatesDecibel Cannabis Company Inc. (TSXV:DB) acquired Agmedica Bioscience Inc. from Callisto Capital Corp for CAD 6.3 million.Decibel Cannabis Company Inc. (TSXV:DB) acquired Agmedica Bioscience Inc. from Callisto Capital Corp for CAD 6.3 million on October 28, 2024. in exchange for a $6.3 million unsecured convertible debenture (the “Convertible Debenture”). The conversion of the Convertible Debenture into common shares in the capital of the Company (each, a “Common Share”) is contingent upon the Company obtaining each of the following: (i) the final approval of the TSX Venture Exchange (the “TSXV”) in respect of the Transaction; and (ii), if applicable, the approval of the disinterested shareholders of the Company in accordance with the rules and policies of the TSXV, which approval. Decibel Cannabis Company Inc. (TSXV:DB) completed the acquisition of Agmedica Bioscience Inc. from Callisto Capital Corp for CAD 6.3 million on October 28, 2024.공시 • Oct 28Decibel Cannabis Company Inc. to Report Q3, 2024 Results on Nov 21, 2024Decibel Cannabis Company Inc. announced that they will report Q3, 2024 results on Nov 21, 2024공시 • Oct 14Decibel Cannabis Company Inc., Annual General Meeting, Nov 28, 2024Decibel Cannabis Company Inc., Annual General Meeting, Nov 28, 2024.분석 기사 • Oct 13Investors Don't See Light At End Of Decibel Cannabis Company Inc.'s (CVE:DB) Tunnel And Push Stock Down 29%Decibel Cannabis Company Inc. ( CVE:DB ) shares have had a horrible month, losing 29% after a relatively good period...공시 • Sep 11Decibel Cannabis Company Inc. Accepts the Resignation of Warren Matzelle as Chief Product Development and Marketing OfficerDecibel Cannabis Company Inc. accepted the resignation of Warren Matzelle, Chief Product Development and Marketing Officer effective as of September 6th, 2024.Price Target Changed • Sep 02Price target decreased by 14% to CA$0.32Down from CA$0.37, the current price target is an average from 3 analysts. New target price is 387% above last closing price of CA$0.065. Stock is down 62% over the past year. The company is forecast to post earnings per share of CA$0.01 next year compared to a net loss per share of CA$0.0043 last year.New Risk • Aug 23New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: CA$166k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Significant insider selling over the past 3 months (CA$166k sold). Market cap is less than US$100m (CA$30.7m market cap, or US$22.7m).Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.001 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0 (improved from CA$0.001 loss in 2Q 2023). Revenue: CA$22.2m (down 28% from 2Q 2023). Net income: CA$59.0k (up CA$482.0k from 2Q 2023). Profit margin: 0.3% (up from net loss in 2Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.분석 기사 • Aug 15Decibel Cannabis Company Inc. (CVE:DB) Stock's 33% Dive Might Signal An Opportunity But It Requires Some ScrutinyTo the annoyance of some shareholders, Decibel Cannabis Company Inc. ( CVE:DB ) shares are down a considerable 33% in...New Risk • Aug 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risk Market cap is less than US$100m (CA$20.5m market cap, or US$14.9m).분석 기사 • Jul 27Decibel Cannabis (CVE:DB) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Price Target Changed • Jul 07Price target decreased by 12% to CA$0.34Down from CA$0.38, the current price target is an average from 4 analysts. New target price is 463% above last closing price of CA$0.06. Stock is down 54% over the past year. The company is forecast to post earnings per share of CA$0.02 next year compared to a net loss per share of CA$0.0043 last year.분석 기사 • Jun 02Decibel Cannabis Company Inc. (CVE:DB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowShareholders in Decibel Cannabis Company Inc. ( CVE:DB ) had a terrible week, as shares crashed 22% to CA$0.07 in the...Reported Earnings • May 30First quarter 2024 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2023)First quarter 2024 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2023). Revenue: CA$21.0m (down 23% from 1Q 2023). Net income: CA$156.0k (up CA$725.0k from 1Q 2023). Profit margin: 0.7% (up from net loss in 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$38.9m market cap, or US$28.4m).Price Target Changed • May 01Price target decreased by 7.4% to CA$0.42Down from CA$0.45, the current price target is an average from 3 analysts. New target price is 233% above last closing price of CA$0.13. Stock is down 3.8% over the past year. The company is forecast to post earnings per share of CA$0.04 next year compared to a net loss per share of CA$0.0043 last year.Reported Earnings • Apr 30Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.011 loss in FY 2022)Full year 2023 results: CA$0.004 loss per share (improved from CA$0.011 loss in FY 2022). Revenue: CA$116.0m (up 46% from FY 2022). Net loss: CA$1.77m (loss narrowed 60% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.공시 • Apr 11Fire & Flower Inc completed the acquisition of brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB).Fire & Flower Inc entered into a binding agreement to acquire brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) for CAD 3 million on March 22, 2024. The transaction is subjected to customary closing conditions and expected to close before the end of Q1 2024.Fire & Flower Inc completed the acquisition of brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) on April 10, 2024.공시 • Apr 09Decibel Cannabis Company Inc. Appoints Benjamin Sze as Chief Executive OfficerDecibel Cannabis Company Inc. announced the appointment of Benjamin Sze as its Chief Executive Officer, effective April 8, 2024. Mr. Sze's transition into the role is expected to be very familiar for both him and the Company as Mr. Sze previously served as the CEO of Decibel before resigning in late 2020 to focus on the health of his family. Former CEO Paul Wilson will be assisting Mr. Sze in handing off leadership of the Company.공시 • Mar 26Decibel Cannabis Company Announces Retirement of Paul Wilson as Chief Executive OfficerDecibel Cannabis Company Inc. announced that Paul Wilson, the company's Chief Executive Officer has informed the Board of Directors (the "Board") of his intention to retire from the company. As a result of Mr. Wilson's retirement, the Board is preparing a transition plan, with the intention of a new Chief Executive Officer being named in the coming weeks.공시 • Mar 24Fire & Flower Inc entered into a binding agreement to acquire brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) for CAD 3 million.Fire & Flower Inc entered into a binding agreement to acquire brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) for CAD 3 million on March 22, 2024. The transaction is subjected to customary closing conditions and expected to close before the end of Q1 2024.분석 기사 • Mar 06Sentiment Still Eluding Decibel Cannabis Company Inc. (CVE:DB)Decibel Cannabis Company Inc.'s ( CVE:DB ) price-to-sales (or "P/S") ratio of 0.4x may look like a pretty appealing...분석 기사 • Jan 10Here's Why Decibel Cannabis (CVE:DB) Is Weighed Down By Its Debt LoadSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: CA$0.001 (vs CA$0.013 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.001 (down from CA$0.013 in 3Q 2022). Revenue: CA$30.2m (up 65% from 3Q 2022). Net income: CA$413.0k (down 92% from 3Q 2022). Profit margin: 1.4% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.공시 • Oct 05Decibel Cannabis Company Inc. Launches General Admission Blinker Closed Loop Vape SystemDecibel Cannabis Company Inc. announced the launch of General Admission 'Blinker' closed loop vape system of products. These products are expected to be available to order for licensed retailers in British Columbia the week of October 16th, in Ontario on October 19th, in Saskatchewan the week of October 23rd, in Alberta on November 3rd and in Manitoba by mid-November. The initial products expected to be launched for the General Admission Blinker system are: Tiger Blood 0.95g vape pod, Peach Rizz 0.95g vape pod, 5 Loco 0.95g vape pod, Essentials Mixer Pack 4x0.28 vape pods, Social Sampler Pack 4x0.28g vape pods, Blinker Vape Battery. Key Highlights of the General Admission Blinker System include: Large initial assortment of flavours and SKUs which consumers have shown to love in other formats like infused pre-rolls, 510 vape cartridges and edibles, Blinker vape pods will be line priced with existing General Admission 510 vape cartridges, Blinker vape batteries will be priced in-line with standard 510 batteries, making the system comparable in cost to the 510 system for consumers, Smart pod technology reduces common vape issues like, clogging and leaking, with best-in-class airflow, vapour production and flavour.공시 • Oct 01Decibel Cannabis Company Inc. Announces Resignation of Paul Wilson as DirectorDecibel Cannabis Company Inc. announced that it has accepted the resignation of Paul Wilson in respect of his position as a director of the Company. At the Company's July 5, 2023 annual general meeting, Mr. Wilson did not receive a majority of votes for his election as a director and, in accordance with the Company's Majority Voting Policy, Mr. Wilson tendered his conditional resignation as a director of the Company. After careful consideration, the Board of Directors of the Company has decided to accept such resignation.분석 기사 • Sep 28We Think Decibel Cannabis (CVE:DB) Is Taking Some Risk With Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Recent Insider Transactions • Aug 25Independent Chairman of the Board recently bought CA$119k worth of stockOn the 21st of August, Shawn Dym bought around 815k shares on-market at roughly CA$0.15 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$456k worth in shares.New Risk • Aug 19New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.7x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$57.2m market cap, or US$42.2m).Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.005 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.005 loss in 2Q 2022). Revenue: CA$30.9m (up 67% from 2Q 2022). Net loss: CA$423.0k (loss narrowed 80% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.분석 기사 • Jul 15Cautious Investors Not Rewarding Decibel Cannabis Company Inc.'s (CVE:DB) Performance CompletelyThere wouldn't be many who think Decibel Cannabis Company Inc.'s ( CVE:DB ) price-to-sales (or "P/S") ratio of 0.7x is...공시 • Jul 06Decibel Cannabis Company Inc. Launches General Admission EdiblesDecibel Cannabis Company Inc. announced the launch of General Admission edibles that are expected to be available to order for licensed retailers in British Columbia the week of July 3rd, in Alberta on July 7th, in Saskatchewan the week of July 24th and in Ontario in August. Tiger Blood 2 Pack Soft Chews - 10mg of THC per pack. Blue Rocket 2 Pack Soft Chews- 10mg of THC per pack; Pomegranate Dragon Fruit 2 Pack Soft Chews -10mg of THC & 5mg of CBN per pack; Pineapple Guava 2 Pack Soft Chews - 9mg of THC & 10mg CBD per pack. In addition to the launch of edibles, Decibel has launched a brand-new website for General Admission. The website, serves as a hub of information, allowing consumers to explore the full range of products, learn about the latest releases, and stay in-touch with the brand.Recent Insider Transactions • Jun 16Chairman of the Board recently bought CA$2.4m worth of stockOn the 12th of June, Shawn Dym bought around 188k shares on-market at roughly CA$12.97 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$2.7m worth in shares.Reported Earnings • May 31First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.011 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (improved from CA$0.011 loss in 1Q 2022). Revenue: CA$27.1m (up 63% from 1Q 2022). Net loss: CA$569.0k (loss narrowed 87% from 1Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.분석 기사 • May 17Is Decibel Cannabis (CVE:DB) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Apr 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: CA$0.011 loss per share (down from CA$0.005 profit in FY 2021). Revenue: CA$79.3m (up 51% from FY 2021). Net loss: CA$4.46m (down 356% from profit in FY 2021). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Jan 13Chairman of the Board recently bought CA$53k worth of stockOn the 6th of January, Shawn Dym bought around 500k shares on-market at roughly CA$0.10 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.Recent Insider Transactions • Dec 26Chairman of the Board recently bought CA$51k worth of stockOn the 22nd of December, Shawn Dym bought around 537k shares on-market at roughly CA$0.095 per share. This transaction increased Shawn's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$94k worth in shares.공시 • Dec 13Decibel Cannabis Company Inc. Announces Board ChangesDecibel Cannabis Company Inc. announced that at its AGM held on December 9, 2022, Shawn Dym has been appointed and agreed to serve as the company's Chairman, and each of Nadia Vattovaz and Jakob Ripshtein have been appointed and agreed to serve, respectively, as chair of the company's Audit Committee and of its Governance, Compensation and Nominating Committee.Board Change • Nov 23Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Ivan Casselman was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: CA$0.013 (vs CA$0.003 loss in 3Q 2021)Third quarter 2022 results: EPS: CA$0.013 (up from CA$0.003 loss in 3Q 2021). Revenue: CA$18.3m (up 37% from 3Q 2021). Net income: CA$5.17m (up CA$6.08m from 3Q 2021). Profit margin: 28% (up from net loss in 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada.분석 기사 • Nov 11Decibel Cannabis (CVE:DB) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...공시 • Oct 14Decibel Cannabis Company Inc., Annual General Meeting, Dec 09, 2022Decibel Cannabis Company Inc., Annual General Meeting, Dec 09, 2022.Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.002 loss in 2Q 2021)Second quarter 2022 results: CA$0.005 loss per share (down from CA$0.002 loss in 2Q 2021). Revenue: CA$18.6m (up 49% from 2Q 2021). Net loss: CA$2.11m (loss widened 241% from 2Q 2021). Over the next year, revenue is forecast to grow 44%, compared to a 24% growth forecast for the Pharmaceuticals industry in Canada.Board Change • Aug 12Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Chairman Cody Church is the most experienced director on the board, commencing their role in 2019. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.분석 기사 • Jul 22Decibel Cannabis (CVE:DB) Use Of Debt Could Be Considered RiskyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...공시 • Jul 14+ 1 more updateDecibel Cannabis Company Inc. to Report Q2, 2022 Results on Aug 18, 2022Decibel Cannabis Company Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 18, 2022공시 • Jul 01Decibel Cannabis Company Inc., Annual General Meeting, Sep 01, 2022Decibel Cannabis Company Inc., Annual General Meeting, Sep 01, 2022.Reported Earnings • May 26First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: CA$0.011 loss per share (down from CA$0.008 profit in 1Q 2021). Revenue: CA$16.7m (up 32% from 1Q 2021). Net loss: CA$4.37m (down 267% from profit in 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 49%, compared to a 86% growth forecast for the industry in Canada.공시 • May 20Decibel Cannabis Company Inc. to Report Q1, 2022 Results on May 25, 2022Decibel Cannabis Company Inc. announced that they will report Q1, 2022 results Pre-Market on May 25, 2022Reported Earnings • Apr 27Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CA$0.005 (up from CA$0.026 loss in FY 2020). Revenue: CA$52.5m (up 75% from FY 2020). Net income: CA$1.74m (up CA$11.0m from FY 2020). Profit margin: 3.3% (up from net loss in FY 2020). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 47%, compared to a 102% growth forecast for the pharmaceuticals industry in Canada.Board Change • Apr 27High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Cody Church is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 23Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CA$0.005 (up from CA$0.026 loss in FY 2020). Revenue: CA$52.5m (up 75% from FY 2020). Net income: CA$1.74m (up CA$11.0m from FY 2020). Profit margin: 3.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 47%, compared to a 107% growth forecast for the pharmaceuticals industry in Canada.공시 • Apr 09Decibel Cannabis Company Inc. to Report Q4, 2021 Results on Apr 22, 2022Decibel Cannabis Company Inc. announced that they will report Q4, 2021 results Pre-Market on Apr 22, 2022공시 • Feb 01Decibel Cannabis Company Inc. Provides Earning Guidance for 2022Decibel Cannabis Company Inc. provided earning guidance for 2022. for the year, the company expected Driving high double digit revenue growth through broader distribution and a new, unique, and innovative product pipeline.Recent Insider Transactions • Jan 28Independent Director recently bought CA$94k worth of stockOn the 24th of January, Michael Kelly bought around 673k shares on-market at roughly CA$0.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$685k more in shares than they have sold in the last 12 months.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Decibel Cannabis previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of CA$6.85m in 2022. Average annual earnings growth of 65% is required to achieve expected profit on schedule.이익 및 매출 성장 예측TSXV:DB - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028156272526312/31/2027147131517412/31/20261335-9143/31/2026121-3-8-6N/A12/31/2025113-367N/A9/30/20251091224N/A6/30/20251011334N/A3/31/2025931212N/A12/31/2024931434N/A9/30/202492-156N/A6/30/202496-145N/A3/31/2024102-145N/A12/31/2023106-257N/A9/30/2023107-435N/A6/30/202398146N/A3/31/202388-158N/A12/31/202279-458N/A9/30/202268-1-23N/A6/30/202263-7-11-6N/A3/31/202256-5-15-11N/A12/31/2021522-20-17N/A9/30/202150-1-13-10N/A6/30/202144-1-8-6N/A3/31/202138-3-5-2N/A12/31/202030-9-9-4N/A9/30/202020-14-11-6N/A6/30/202015-13-8-5N/A3/31/202011-9-9-7N/A12/31/20196-7N/A-1N/A9/30/20195-1N/A0N/A6/30/20192-1N/A-3N/A3/31/20191-3N/A-3N/A12/31/20180-3N/A-3N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: DB 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: DB (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: DB 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: DB 의 수익(연간 7.1%)이 Canadian 시장(연간 4.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: DB 의 수익(연간 7.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: DB의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/29 22:53종가2026/06/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Decibel Cannabis Company Inc.는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Frederico Yokota Choucair GomesATB CormarkKimberly Thompson-HedlinCanaccord GenuityNeal GilmerHaywood Securities Inc.4명의 분석가 더 보기
공시 • May 23Decibel Cannabis Company Inc. Provides Earnings Guidance for the Second Quarter of 2026 and Reaffirms Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the second quarter of 2026 and reaffirms earnings guidance for the full year 2026. For the quarter, the company expects net revenue of $33 million to $35 million, implying year over year growth of 14% to midpoint of range. For the full year guidance, the company expects net revenue of $130 million to $135 million.
Price Target Changed • Apr 19Price target increased by 7.7% to CA$0.23Up from CA$0.22, the current price target is an average from 3 analysts. New target price is 73% above last closing price of CA$0.14. Stock is up 125% over the past year. The company is forecast to post earnings per share of CA$0.015 next year compared to a net loss per share of CA$0.0051 last year.
공시 • Apr 18Decibel Cannabis Company Inc. Provides Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the full year 2026. For the period, the company expects Net Revenue of $130 to $135 million, implying growth of 18% to midpoint of range.
Price Target Changed • Apr 07Price target decreased by 7.1% to CA$0.22Down from CA$0.23, the current price target is an average from 3 analysts. New target price is 67% above last closing price of CA$0.13. Stock is up 117% over the past year. The company is forecast to post earnings per share of CA$0 for next year compared to CA$0.032 last year.
공시 • Nov 20Decibel Cannabis Company Inc. Revises Revenue Guidance for Full Year 2025Decibel Cannabis Company Inc. revised revenue guidance for full year 2025. For the period, the company expects revenue of approximately USD 115 million compared to previous guidance of USD 130 million.
공시 • May 22Decibel Cannabis Company Inc. Announces Earnings Guidance for the Full Year 2025Decibel Cannabis Company Inc. announced earnings guidance for the full year 2025. For the year,the company expects Net Revenue of $130 million driven by continued international growth.
공시 • May 23Decibel Cannabis Company Inc. Provides Earnings Guidance for the Second Quarter of 2026 and Reaffirms Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the second quarter of 2026 and reaffirms earnings guidance for the full year 2026. For the quarter, the company expects net revenue of $33 million to $35 million, implying year over year growth of 14% to midpoint of range. For the full year guidance, the company expects net revenue of $130 million to $135 million.
Reported Earnings • May 22First quarter 2026 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 1Q 2025)First quarter 2026 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 1Q 2025). Revenue: CA$29.8m (up 41% from 1Q 2025). Net loss: CA$2.18m (loss widened 14% from 1Q 2025). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
New Risk • May 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$7.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CA$7.9m free cash flow). Minor Risk Market cap is less than US$100m (CA$75.0m market cap, or US$54.3m).
공시 • May 13Decibel Cannabis Company Inc. to Report Q1, 2026 Results on May 21, 2026Decibel Cannabis Company Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
Price Target Changed • Apr 19Price target increased by 7.7% to CA$0.23Up from CA$0.22, the current price target is an average from 3 analysts. New target price is 73% above last closing price of CA$0.14. Stock is up 125% over the past year. The company is forecast to post earnings per share of CA$0.015 next year compared to a net loss per share of CA$0.0051 last year.
공시 • Apr 18Decibel Cannabis Company Inc. Provides Earnings Guidance for the Full Year 2026Decibel Cannabis Company Inc. provided earnings guidance for the full year 2026. For the period, the company expects Net Revenue of $130 to $135 million, implying growth of 18% to midpoint of range.
Reported Earnings • Apr 17Full year 2025 earnings released: CA$0.005 loss per share (vs CA$0.032 profit in FY 2024)Full year 2025 results: CA$0.005 loss per share (down from CA$0.032 profit in FY 2024). Revenue: CA$112.7m (up 22% from FY 2024). Net loss: CA$2.92m (down 122% from profit in FY 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공시 • Apr 08Decibel Cannabis Company Inc. to Report Q4, 2025 Results on Apr 16, 2026Decibel Cannabis Company Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 16, 2026
Price Target Changed • Apr 07Price target decreased by 7.1% to CA$0.22Down from CA$0.23, the current price target is an average from 3 analysts. New target price is 67% above last closing price of CA$0.13. Stock is up 117% over the past year. The company is forecast to post earnings per share of CA$0 for next year compared to CA$0.032 last year.
분석 기사 • Jan 23Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Nov 26Impressive Earnings May Not Tell The Whole Story For Decibel Cannabis (CVE:DB)Despite announcing strong earnings, Decibel Cannabis Company Inc.'s ( CVE:DB ) stock was sluggish. Our analysis...
Reported Earnings • Nov 20Third quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: CA$0.002 loss per share (further deteriorated from CA$0.001 loss in 3Q 2024). Revenue: CA$32.9m (up 37% from 3Q 2024). Net loss: CA$1.34m (loss widened 152% from 3Q 2024). Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
공시 • Nov 20Decibel Cannabis Company Inc. Revises Revenue Guidance for Full Year 2025Decibel Cannabis Company Inc. revised revenue guidance for full year 2025. For the period, the company expects revenue of approximately USD 115 million compared to previous guidance of USD 130 million.
공시 • Nov 07Decibel Cannabis Company Inc. to Report Q3, 2025 Results on Nov 19, 2025Decibel Cannabis Company Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 19, 2025
분석 기사 • Oct 31Potential Upside For Decibel Cannabis Company Inc. (CVE:DB) Not Without RiskThere wouldn't be many who think Decibel Cannabis Company Inc.'s ( CVE:DB ) price-to-sales (or "P/S") ratio of 0.8x is...
공시 • Oct 07Decibel Cannabis Company Inc., Annual General Meeting, Dec 11, 2025Decibel Cannabis Company Inc., Annual General Meeting, Dec 11, 2025.
Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: CA$0.003 (vs CA$0 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.003 (up from CA$0 in 2Q 2024). Revenue: CA$29.8m (up 35% from 2Q 2024). Net income: CA$1.65m (up CA$1.59m from 2Q 2024). Profit margin: 5.5% (up from 0.3% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.3% operating cash flow to total debt). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$60.6m market cap, or US$43.9m).
분석 기사 • Jul 15A Piece Of The Puzzle Missing From Decibel Cannabis Company Inc.'s (CVE:DB) 29% Share Price ClimbDecibel Cannabis Company Inc. ( CVE:DB ) shares have continued their recent momentum with a 29% gain in the last month...
분석 기사 • Jul 09Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Recent Insider Transactions • Jun 08Independent Chairman of the Board recently bought CA$146k worth of stockOn the 5th of June, Shawn Dym bought around 2m shares on-market at roughly CA$0.07 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Shawn's only on-market trade for the last 12 months.
Reported Earnings • May 23First quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0 in 1Q 2024)First quarter 2025 results: CA$0.003 loss per share (further deteriorated from CA$0 in 1Q 2024). Revenue: CA$21.2m (up 1.4% from 1Q 2024). Net loss: CA$1.90m (down CA$2.06m from profit in 1Q 2024). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
공시 • May 22Decibel Cannabis Company Inc. Announces Earnings Guidance for the Full Year 2025Decibel Cannabis Company Inc. announced earnings guidance for the full year 2025. For the year,the company expects Net Revenue of $130 million driven by continued international growth.
분석 기사 • Apr 30Concerns Surrounding Decibel Cannabis' (CVE:DB) PerformanceFollowing the solid earnings report from Decibel Cannabis Company Inc. ( CVE:DB ), the market responded by bidding up...
공시 • Apr 23Decibel Cannabis Company Inc. Reiterates Earnings Guidance for the Full Year 2025Decibel Cannabis Company Inc. reiterated earnings guidance for the full year 2025. For the period, the company expects Net Revenue of $130 million driven by continued international growth.
Reported Earnings • Apr 23Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: CA$0.032 (up from CA$0.004 loss in FY 2023). Revenue: CA$92.5m (down 20% from FY 2023). Net income: CA$13.6m (up CA$15.4m from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 12Market Cool On Decibel Cannabis Company Inc.'s (CVE:DB) Revenues Pushing Shares 27% LowerThe Decibel Cannabis Company Inc. ( CVE:DB ) share price has fared very poorly over the last month, falling by a...
분석 기사 • Feb 26Take Care Before Diving Into The Deep End On Decibel Cannabis Company Inc. (CVE:DB)With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Pharmaceuticals industry in Canada, you could be...
Price Target Changed • Jan 19Price target decreased by 16% to CA$0.27Down from CA$0.32, the current price target is an average from 3 analysts. New target price is 281% above last closing price of CA$0.07. Stock is down 46% over the past year. The company is forecast to post earnings per share of CA$0.005 next year compared to a net loss per share of CA$0.0043 last year.
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 41% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (CA$46.1m market cap, or US$32.2m).
Board Change • Jan 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Nadia Vattovaz is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Dec 17Price target decreased by 16% to CA$0.27Down from CA$0.32, the current price target is an average from 3 analysts. New target price is 281% above last closing price of CA$0.07. Stock is down 46% over the past year. The company is forecast to post earnings per share of CA$0.005 next year compared to a net loss per share of CA$0.0043 last year.
공시 • Dec 11Decibel Cannabis Company Inc. Announces Committee ChangesDecibel Cannabis Company Inc. announced that at the annual and special meeting of shareholders held on December 10, 2024 Subsequent to the Meeting, Shawn Dym, Nadia Vattovaz and Jakob Ripshtein have been appointed and agreed to serve on the Corporation's committees, with Ms. Vattovaz to serve as chair of the Company's Audit Committee, and Mr. Ripshtein to serve as chair of its Governance, Compensation and Nominating Committee.
공시 • Nov 25Decibel Cannabis Company Inc. announced that it has received CAD 3.189099 million in fundingOn November 25, 2024, Decibel Cannabis Company Inc. closed the transaction. The company issued 19,647,776 Common Shares in the capital of the Company at an issue price of CAD 0.06 per share for the gross proceeds of up to CAD 1,178,867 in its final tranche. No finders' fees were paid in connection with either the first or second closing of the Offering. The Offering is subject to the receipt of all regulatory approvals including the final approval of the TSX Venture Exchange. Certain directors and officers of the Company subscribed for an aggregate of 19,460,061 Common shares in the first and second closings of the Offering.
Reported Earnings • Nov 22Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.001 profit in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (down from CA$0.001 profit in 3Q 2023). Revenue: CA$24.1m (down 20% from 3Q 2023). Net loss: CA$531.0k (down 229% from profit in 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Nov 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Shareholders have been diluted in the past year (8.2% increase in shares outstanding). Market cap is less than US$100m (CA$31.0m market cap, or US$22.3m).
공시 • Oct 29+ 3 more updatesDecibel Cannabis Company Inc. (TSXV:DB) acquired Agmedica Bioscience Inc. from Callisto Capital Corp for CAD 6.3 million.Decibel Cannabis Company Inc. (TSXV:DB) acquired Agmedica Bioscience Inc. from Callisto Capital Corp for CAD 6.3 million on October 28, 2024. in exchange for a $6.3 million unsecured convertible debenture (the “Convertible Debenture”). The conversion of the Convertible Debenture into common shares in the capital of the Company (each, a “Common Share”) is contingent upon the Company obtaining each of the following: (i) the final approval of the TSX Venture Exchange (the “TSXV”) in respect of the Transaction; and (ii), if applicable, the approval of the disinterested shareholders of the Company in accordance with the rules and policies of the TSXV, which approval. Decibel Cannabis Company Inc. (TSXV:DB) completed the acquisition of Agmedica Bioscience Inc. from Callisto Capital Corp for CAD 6.3 million on October 28, 2024.
공시 • Oct 28Decibel Cannabis Company Inc. to Report Q3, 2024 Results on Nov 21, 2024Decibel Cannabis Company Inc. announced that they will report Q3, 2024 results on Nov 21, 2024
공시 • Oct 14Decibel Cannabis Company Inc., Annual General Meeting, Nov 28, 2024Decibel Cannabis Company Inc., Annual General Meeting, Nov 28, 2024.
분석 기사 • Oct 13Investors Don't See Light At End Of Decibel Cannabis Company Inc.'s (CVE:DB) Tunnel And Push Stock Down 29%Decibel Cannabis Company Inc. ( CVE:DB ) shares have had a horrible month, losing 29% after a relatively good period...
공시 • Sep 11Decibel Cannabis Company Inc. Accepts the Resignation of Warren Matzelle as Chief Product Development and Marketing OfficerDecibel Cannabis Company Inc. accepted the resignation of Warren Matzelle, Chief Product Development and Marketing Officer effective as of September 6th, 2024.
Price Target Changed • Sep 02Price target decreased by 14% to CA$0.32Down from CA$0.37, the current price target is an average from 3 analysts. New target price is 387% above last closing price of CA$0.065. Stock is down 62% over the past year. The company is forecast to post earnings per share of CA$0.01 next year compared to a net loss per share of CA$0.0043 last year.
New Risk • Aug 23New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: CA$166k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Significant insider selling over the past 3 months (CA$166k sold). Market cap is less than US$100m (CA$30.7m market cap, or US$22.7m).
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.001 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0 (improved from CA$0.001 loss in 2Q 2023). Revenue: CA$22.2m (down 28% from 2Q 2023). Net income: CA$59.0k (up CA$482.0k from 2Q 2023). Profit margin: 0.3% (up from net loss in 2Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 15Decibel Cannabis Company Inc. (CVE:DB) Stock's 33% Dive Might Signal An Opportunity But It Requires Some ScrutinyTo the annoyance of some shareholders, Decibel Cannabis Company Inc. ( CVE:DB ) shares are down a considerable 33% in...
New Risk • Aug 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risk Market cap is less than US$100m (CA$20.5m market cap, or US$14.9m).
분석 기사 • Jul 27Decibel Cannabis (CVE:DB) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Price Target Changed • Jul 07Price target decreased by 12% to CA$0.34Down from CA$0.38, the current price target is an average from 4 analysts. New target price is 463% above last closing price of CA$0.06. Stock is down 54% over the past year. The company is forecast to post earnings per share of CA$0.02 next year compared to a net loss per share of CA$0.0043 last year.
분석 기사 • Jun 02Decibel Cannabis Company Inc. (CVE:DB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowShareholders in Decibel Cannabis Company Inc. ( CVE:DB ) had a terrible week, as shares crashed 22% to CA$0.07 in the...
Reported Earnings • May 30First quarter 2024 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2023)First quarter 2024 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2023). Revenue: CA$21.0m (down 23% from 1Q 2023). Net income: CA$156.0k (up CA$725.0k from 1Q 2023). Profit margin: 0.7% (up from net loss in 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$38.9m market cap, or US$28.4m).
Price Target Changed • May 01Price target decreased by 7.4% to CA$0.42Down from CA$0.45, the current price target is an average from 3 analysts. New target price is 233% above last closing price of CA$0.13. Stock is down 3.8% over the past year. The company is forecast to post earnings per share of CA$0.04 next year compared to a net loss per share of CA$0.0043 last year.
Reported Earnings • Apr 30Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.011 loss in FY 2022)Full year 2023 results: CA$0.004 loss per share (improved from CA$0.011 loss in FY 2022). Revenue: CA$116.0m (up 46% from FY 2022). Net loss: CA$1.77m (loss narrowed 60% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
공시 • Apr 11Fire & Flower Inc completed the acquisition of brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB).Fire & Flower Inc entered into a binding agreement to acquire brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) for CAD 3 million on March 22, 2024. The transaction is subjected to customary closing conditions and expected to close before the end of Q1 2024.Fire & Flower Inc completed the acquisition of brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) on April 10, 2024.
공시 • Apr 09Decibel Cannabis Company Inc. Appoints Benjamin Sze as Chief Executive OfficerDecibel Cannabis Company Inc. announced the appointment of Benjamin Sze as its Chief Executive Officer, effective April 8, 2024. Mr. Sze's transition into the role is expected to be very familiar for both him and the Company as Mr. Sze previously served as the CEO of Decibel before resigning in late 2020 to focus on the health of his family. Former CEO Paul Wilson will be assisting Mr. Sze in handing off leadership of the Company.
공시 • Mar 26Decibel Cannabis Company Announces Retirement of Paul Wilson as Chief Executive OfficerDecibel Cannabis Company Inc. announced that Paul Wilson, the company's Chief Executive Officer has informed the Board of Directors (the "Board") of his intention to retire from the company. As a result of Mr. Wilson's retirement, the Board is preparing a transition plan, with the intention of a new Chief Executive Officer being named in the coming weeks.
공시 • Mar 24Fire & Flower Inc entered into a binding agreement to acquire brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) for CAD 3 million.Fire & Flower Inc entered into a binding agreement to acquire brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB) for CAD 3 million on March 22, 2024. The transaction is subjected to customary closing conditions and expected to close before the end of Q1 2024.
분석 기사 • Mar 06Sentiment Still Eluding Decibel Cannabis Company Inc. (CVE:DB)Decibel Cannabis Company Inc.'s ( CVE:DB ) price-to-sales (or "P/S") ratio of 0.4x may look like a pretty appealing...
분석 기사 • Jan 10Here's Why Decibel Cannabis (CVE:DB) Is Weighed Down By Its Debt LoadSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: CA$0.001 (vs CA$0.013 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.001 (down from CA$0.013 in 3Q 2022). Revenue: CA$30.2m (up 65% from 3Q 2022). Net income: CA$413.0k (down 92% from 3Q 2022). Profit margin: 1.4% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
공시 • Oct 05Decibel Cannabis Company Inc. Launches General Admission Blinker Closed Loop Vape SystemDecibel Cannabis Company Inc. announced the launch of General Admission 'Blinker' closed loop vape system of products. These products are expected to be available to order for licensed retailers in British Columbia the week of October 16th, in Ontario on October 19th, in Saskatchewan the week of October 23rd, in Alberta on November 3rd and in Manitoba by mid-November. The initial products expected to be launched for the General Admission Blinker system are: Tiger Blood 0.95g vape pod, Peach Rizz 0.95g vape pod, 5 Loco 0.95g vape pod, Essentials Mixer Pack 4x0.28 vape pods, Social Sampler Pack 4x0.28g vape pods, Blinker Vape Battery. Key Highlights of the General Admission Blinker System include: Large initial assortment of flavours and SKUs which consumers have shown to love in other formats like infused pre-rolls, 510 vape cartridges and edibles, Blinker vape pods will be line priced with existing General Admission 510 vape cartridges, Blinker vape batteries will be priced in-line with standard 510 batteries, making the system comparable in cost to the 510 system for consumers, Smart pod technology reduces common vape issues like, clogging and leaking, with best-in-class airflow, vapour production and flavour.
공시 • Oct 01Decibel Cannabis Company Inc. Announces Resignation of Paul Wilson as DirectorDecibel Cannabis Company Inc. announced that it has accepted the resignation of Paul Wilson in respect of his position as a director of the Company. At the Company's July 5, 2023 annual general meeting, Mr. Wilson did not receive a majority of votes for his election as a director and, in accordance with the Company's Majority Voting Policy, Mr. Wilson tendered his conditional resignation as a director of the Company. After careful consideration, the Board of Directors of the Company has decided to accept such resignation.
분석 기사 • Sep 28We Think Decibel Cannabis (CVE:DB) Is Taking Some Risk With Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Recent Insider Transactions • Aug 25Independent Chairman of the Board recently bought CA$119k worth of stockOn the 21st of August, Shawn Dym bought around 815k shares on-market at roughly CA$0.15 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$456k worth in shares.
New Risk • Aug 19New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.7x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$57.2m market cap, or US$42.2m).
Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.005 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.005 loss in 2Q 2022). Revenue: CA$30.9m (up 67% from 2Q 2022). Net loss: CA$423.0k (loss narrowed 80% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
분석 기사 • Jul 15Cautious Investors Not Rewarding Decibel Cannabis Company Inc.'s (CVE:DB) Performance CompletelyThere wouldn't be many who think Decibel Cannabis Company Inc.'s ( CVE:DB ) price-to-sales (or "P/S") ratio of 0.7x is...
공시 • Jul 06Decibel Cannabis Company Inc. Launches General Admission EdiblesDecibel Cannabis Company Inc. announced the launch of General Admission edibles that are expected to be available to order for licensed retailers in British Columbia the week of July 3rd, in Alberta on July 7th, in Saskatchewan the week of July 24th and in Ontario in August. Tiger Blood 2 Pack Soft Chews - 10mg of THC per pack. Blue Rocket 2 Pack Soft Chews- 10mg of THC per pack; Pomegranate Dragon Fruit 2 Pack Soft Chews -10mg of THC & 5mg of CBN per pack; Pineapple Guava 2 Pack Soft Chews - 9mg of THC & 10mg CBD per pack. In addition to the launch of edibles, Decibel has launched a brand-new website for General Admission. The website, serves as a hub of information, allowing consumers to explore the full range of products, learn about the latest releases, and stay in-touch with the brand.
Recent Insider Transactions • Jun 16Chairman of the Board recently bought CA$2.4m worth of stockOn the 12th of June, Shawn Dym bought around 188k shares on-market at roughly CA$12.97 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$2.7m worth in shares.
Reported Earnings • May 31First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.011 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (improved from CA$0.011 loss in 1Q 2022). Revenue: CA$27.1m (up 63% from 1Q 2022). Net loss: CA$569.0k (loss narrowed 87% from 1Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
분석 기사 • May 17Is Decibel Cannabis (CVE:DB) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Apr 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: CA$0.011 loss per share (down from CA$0.005 profit in FY 2021). Revenue: CA$79.3m (up 51% from FY 2021). Net loss: CA$4.46m (down 356% from profit in FY 2021). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Jan 13Chairman of the Board recently bought CA$53k worth of stockOn the 6th of January, Shawn Dym bought around 500k shares on-market at roughly CA$0.10 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.
Recent Insider Transactions • Dec 26Chairman of the Board recently bought CA$51k worth of stockOn the 22nd of December, Shawn Dym bought around 537k shares on-market at roughly CA$0.095 per share. This transaction increased Shawn's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shawn has been a buyer over the last 12 months, purchasing a net total of CA$94k worth in shares.
공시 • Dec 13Decibel Cannabis Company Inc. Announces Board ChangesDecibel Cannabis Company Inc. announced that at its AGM held on December 9, 2022, Shawn Dym has been appointed and agreed to serve as the company's Chairman, and each of Nadia Vattovaz and Jakob Ripshtein have been appointed and agreed to serve, respectively, as chair of the company's Audit Committee and of its Governance, Compensation and Nominating Committee.
Board Change • Nov 23Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Ivan Casselman was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: CA$0.013 (vs CA$0.003 loss in 3Q 2021)Third quarter 2022 results: EPS: CA$0.013 (up from CA$0.003 loss in 3Q 2021). Revenue: CA$18.3m (up 37% from 3Q 2021). Net income: CA$5.17m (up CA$6.08m from 3Q 2021). Profit margin: 28% (up from net loss in 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada.
분석 기사 • Nov 11Decibel Cannabis (CVE:DB) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Oct 14Decibel Cannabis Company Inc., Annual General Meeting, Dec 09, 2022Decibel Cannabis Company Inc., Annual General Meeting, Dec 09, 2022.
Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.002 loss in 2Q 2021)Second quarter 2022 results: CA$0.005 loss per share (down from CA$0.002 loss in 2Q 2021). Revenue: CA$18.6m (up 49% from 2Q 2021). Net loss: CA$2.11m (loss widened 241% from 2Q 2021). Over the next year, revenue is forecast to grow 44%, compared to a 24% growth forecast for the Pharmaceuticals industry in Canada.
Board Change • Aug 12Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Chairman Cody Church is the most experienced director on the board, commencing their role in 2019. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
분석 기사 • Jul 22Decibel Cannabis (CVE:DB) Use Of Debt Could Be Considered RiskyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Jul 14+ 1 more updateDecibel Cannabis Company Inc. to Report Q2, 2022 Results on Aug 18, 2022Decibel Cannabis Company Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 18, 2022
공시 • Jul 01Decibel Cannabis Company Inc., Annual General Meeting, Sep 01, 2022Decibel Cannabis Company Inc., Annual General Meeting, Sep 01, 2022.
Reported Earnings • May 26First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: CA$0.011 loss per share (down from CA$0.008 profit in 1Q 2021). Revenue: CA$16.7m (up 32% from 1Q 2021). Net loss: CA$4.37m (down 267% from profit in 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 49%, compared to a 86% growth forecast for the industry in Canada.
공시 • May 20Decibel Cannabis Company Inc. to Report Q1, 2022 Results on May 25, 2022Decibel Cannabis Company Inc. announced that they will report Q1, 2022 results Pre-Market on May 25, 2022
Reported Earnings • Apr 27Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CA$0.005 (up from CA$0.026 loss in FY 2020). Revenue: CA$52.5m (up 75% from FY 2020). Net income: CA$1.74m (up CA$11.0m from FY 2020). Profit margin: 3.3% (up from net loss in FY 2020). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 47%, compared to a 102% growth forecast for the pharmaceuticals industry in Canada.
Board Change • Apr 27High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Cody Church is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 23Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CA$0.005 (up from CA$0.026 loss in FY 2020). Revenue: CA$52.5m (up 75% from FY 2020). Net income: CA$1.74m (up CA$11.0m from FY 2020). Profit margin: 3.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 47%, compared to a 107% growth forecast for the pharmaceuticals industry in Canada.
공시 • Apr 09Decibel Cannabis Company Inc. to Report Q4, 2021 Results on Apr 22, 2022Decibel Cannabis Company Inc. announced that they will report Q4, 2021 results Pre-Market on Apr 22, 2022
공시 • Feb 01Decibel Cannabis Company Inc. Provides Earning Guidance for 2022Decibel Cannabis Company Inc. provided earning guidance for 2022. for the year, the company expected Driving high double digit revenue growth through broader distribution and a new, unique, and innovative product pipeline.
Recent Insider Transactions • Jan 28Independent Director recently bought CA$94k worth of stockOn the 24th of January, Michael Kelly bought around 673k shares on-market at roughly CA$0.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$685k more in shares than they have sold in the last 12 months.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Decibel Cannabis previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of CA$6.85m in 2022. Average annual earnings growth of 65% is required to achieve expected profit on schedule.